Thursday, July 14, 2005

Ranbaxy gets permission for AIDS Vaccine

RANBAXY Laboratories Ltd a major brand in pharmaceuticals in both India and interanational market has received tentative approval from the US Food and Drug Administration (FDA) to manufacture and market zidovudine tablets 300 mg used in combination with other anti-retroviral (ARV) agents in the treatment of HIV infection. This is the first approval granted by the US regulator for generic zidovudine and Ranbaxy's third tentative approval under the US President's Emergency Plan for AIDS relief